Additionally, there are clinical studies on the combination of anti-IL-17 antibodies and anti-PD-1 antibodies, such as CPDR001X2103 NCT02900664, which uses PDR001 (PD-1 inhibitor) in combination with CJM112 (anti-IL-17A antibody), canakinumab, and trametinib to treat advanced CRC, triple-negative breast cancer, and non-small cell lung cancer to verify their effects. This evidence concerns the gene IL17A and colorectal carcinoma.